Metal Binder Jetting
Automotive Polymers

Organovo and Johnson & Johnson Team to Evaluate 3D Bio-printed Tissue Use

Share this Article

It’s only a matter of time before 3D bio-printing really takes off. One of the leaders in the space is Organovo, a company who has already been able to 3D print living liver tissue, and has an ultimate goal of 3D printing a org-2functioning liver for transplantation within a human being.

Before we get there though, there are many useful applications to 3D printed living tissue, which can already be used today. One such application is that of drug discovery testing. Every year billions of dollars are spent performing clinical trials on potential new drugs for the market. Many of these trials involve human beings, oftentimes being put at some risk. Liver toxicity testing, in particular, is usually performed using tissue samples from cadavers, meaning it’s not all that easy to obtain such samples. What 3D bio-printing enables researchers to do, is create live human tissue, which can then be used as a test bed to discover any negative reactions a particular drug may have on that tissue. Once scaled up, such a process could make available as much tissue as is needed for research, as well as tissue of extremely high quality.

org-feat

Organovo has been leading the way in this space. They have been working for years to perfect the 3D printing techniques required to produce high quality tissue, which is able to stay alive over a long period of time. org-1Today, the company announced an agreement with one of the largest pharmaceutical corporations on the planet, Johnson & Johnson. The actual agreement was signed between Organovo and Janssen Research and Development (JRD), a pharmaceutical company of Johnson & Johnson.

Under this agreement, of which the exact terms have not yet been disclosed, the companies will work together to evaluate the use of 3D bio-printed tissue in a drug discovery setting. Just what kind of tissue, and to what extent the testing will be done, is yet to be seen, however, it certainly bodes well for the progress of 3D bio-printing technology. To have a major, globally recognizable, corporation like Johnson & Johnson on board, could push the adoption of this technology, as well as its progress to a whole to level. It is interesting to note that following the release of an 8K filing disclosing this agreement this morning, shares of Organovo are up over 11%.

What will the implications of this agreement be? Let’s hear your opinions in the Organovo/Johnson & Johnson forum thread on 3DPB.com.

Share this Article


Recent News

3D Printing News Unpeeled, Live with Joris Peels Monday 15th of August

Velo3D CEO Benny Buller on Impressive Q2 Earnings – AMS Focus



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

3D Printing News Unpeeled, Live with Joris Peels Friday 12th of August

Today we will be talking about a model of a cranium, Prellis Biologics new raise, 3D printing actuators for a hand that moves like a human one as well as...

Metal 3D Printing Firm Velo3D Announces Impressive Q2 Earning

US financial markets appear to be in a state of limbo. For one thing, there are few clear opinions circulating concerning the question as to whether the American economy is,...

3D Printing News Unpeeled, Live with Joris Peels Thursday 11th of August

Today we’re going to discuss 3D printed sunglasses from Givenchy, 3D printing drone swarms, more sustainable 3D printing materials for buildings by ORNL, 3D printing earnings season and more.  

Stratasys Goes on the Record on Buying Covestro 3D Printing Materials Unit

In light of the recent acquisition of Covestro’s additive manufacturing (AM) business by Stratasys, we interviewed executive vice president of Product Strategy and Corporate Development at Stratasys Omer Krieger and...